TNFSF10 and neoplasm: Therefore, we hypothesized that genetic fusion of a monoclonal CD19-directed IgG antibody to monovalent single-chain (sc) TRAIL generates a fusion protein that combines the specificity and beneficial pharmacokinetics of an IgG antibody with the cytotoxic activity of a tumor-cell-specific death ligand.